Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

J-LANCELOT, 2010 - atopaxar vs placebo

CURRENT - OASIS 7 (ASA), 2010 - ASA high dose vs ASA low dose

CURRENT OASIS 7 (clopidogrel), 2010 - clopidogrel double-dose vs clopidogrel standard-dose

PLATO, 2009 - ticagrelor + aspirin vs clopidogrel + aspirin

ATLAS ACS-TIMI 46, 2009 - rivaroxaban vs placebo

APPRAISE-1 (2.5 mg bid), 2009 - apixaban vs placebo

APPRAISE-1 (10mg od), 2009 - apixaban vs placebo

SEPIA-ACS1 TIMI 42, 2009 - otamixaban vs unfractioned heparin

DISPERSE-2 (90mg), 2007 - ticagrelor + aspirin vs clopidogrel + aspirin

OASIS 5, 2006 - fondaparinux vs enoxaparin

PROTECT-TIMI 30, 2006 - Bivalirudin vs eptifibatide + heparin

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

SYNERGY, 2005 - enoxaparin vs UFH (on top of aspirin)

EVET, 2005 - enoxaparin vs tinzaparin

LoWASA, 2004 - warfarin vs control (on top of aspirin)

PENTUA, 2004 - fondaparinux vs enoxaparin

Zibaeenezhad, 2004 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin+asp vs asp), 2002 - coumadin vs control (on top of aspirin)

WARIS, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin vs aspirin), 2002 - coumadin vs aspirin

CHAMP, 2002 - warfarin vs control (on top of aspirin)

APRICOT-2, 2002 - warfarin vs control (on top of aspirin)

OASIS-2 Warfarin Substudy, 2001 - warfarin vs control (on top of aspirin)

CURE, 2001 - clopidogrel + aspirin vs aspirin

Huyhn, 2001 - warfarin vs placebo (on top of aspirin)



See also:

  • All acute coronary syndrome clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of warfarin
    		•  

    Huyhn study, 2001

    Treatments

    Studied treatment warfarin adjusted dose for INR 2–2.5 +aspirin
    Control treatment placebo +aspirin
    Concomittant treatment aspirin 80 mg daily

    Patients

    Patients UA, NSTEMI with prior CABG

    Method and design

    Randomized effectives 44 / 46 (studied vs. control)
    Blinding double blind
    Follow-up duration 1 year
    Lost to follow-up 2.2%


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Major bleeding

    2 / 44
         0 / 46
         classic 9,41 [0,15;574,21]

    all cause death, non-fatal MI, thrombo-embolic stroke

    2 / 44
         1 / 46
         classic 2,09 [0,20;22,25]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Major bleeding 2 / 44 (4,5%) 0 / 46 (1,1%) 4,18 [0,19;90,21]   8504 
    all cause death, non-fatal MI, thrombo-embolic stroke 2 / 44 (4,5%) 1 / 46 (2,2%) 2,09 [0,20;22,25]   8504 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 8504: Andreotti F, Testa L, Biondi-Zoccai GG, Crea FAspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients.Eur Heart J 2006;27:519-26
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    all cause death, non-fatal MI, thrombo-embolic stroke 4,55% 2,17% 2,4%


    Reference(s)

    Trials register # NA
    • Huynh T, Théroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery.. Circulation 2001;103:3069-74
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend